Menu
NuVision Biotherapies
NuVision has developed a unique way to process and preserve amnion which can be applied to the surface of the eye to promote healing of ‘front of eye’ disease and trauma.
Biotherapy
School of Medicine
Profile
Prior to NuVision, cryopreserved amnion had to be stored in specialist facilities. Delivery of the amnion had to be within thawing time before surgery which is a constraint for the NHS and meant the treatment could only be used for scheduled surgery.
NuVision’s first product, Omnigen® is a dry, sterile disc that does not require specialist storage conditions.
Omnigen® has further potential for use in human and veterinary treatments for conditions that feature chronic pain or inflammation, and flexible storage conditions potentially make it suitable for remote emergency treatment by military surgeons.
@NuVisBio on Twitter
In a post-COVID world @NuVisBio wanted to create something to speed up health procedures, reduce the need for consultations & surgeries AND improve patient outcomes... nailed it! Find out more >
#covid19solutions #healthcareinnovation #HomeToTheCurious
MediCity based NuVision to cut hospital waiting lists with new products
NuVision could speed up treatment while reducing the impact on hospital waiting lists and patient visits following COVID-19 restrictions.
ow.ly
📰| A major new health study to be launched with @AstonOptometry in a bid to help millions who suffer from ‘dry eye’ 👁🚑
#TeamAston Professor James Wolffsohn and @UniofNottingham spin out @NuVisBio testing a new innovation for dry eye sufferers 🔬
➡https://bit.ly/3795m6o
UK researchers @AstonUniversity collaborate with the @UniofNottingham spinout company @NuVisBio in a two-week trial of a contact lens that applies a material derived from amniotic membrane. http://ow.ly/j41z30rfv7n #optometry #OT
@ClearerOptics @OptometryToday @AstonUniversity @UniofNottingham Omnigen is a non-living biological matrix derived from human amniotic membrane tissue. It doesn’t not contain living cells but retains the anti-inflammatory and wound healing properties of amnion.
@MedilinkEM @MedilinkWM @EM_AHSN @BioCity @bbcemt @BBCFergusWalsh
[email protected] spin-out and @Mercia_PLC @MidsEngInv investee company @NuVisBio to cut hospital waiting lists with new products @BioCity @MedilinkEM @D2N2GrowthHub @D2N2LEP #MEIF
https://www.thebusinessdesk.com/eastmidlands/news/2040799-university-spin-out-to-cut-hospital-waiting-lists-with-new-products#.X034LprMqV0.twitter via @tbdeastmidlands
Homepage - Midlands Engine Investment Fund
What is the Midlands Engine Investment Fund? The Midlands Engine Investment Fund (MEIF), supported by the European Regional Development Fund, provid...
www.meif.co.uk
@NuVisBio develop ground breaking regenerative biotherapies to treat ocular surface disease & wounds. @EM_AHSN have helped them to commercialise their tissue reconstruction product, now used at 54 NHS sites. Read more: http://ow.ly/9pzR50BgNxb
#ResetRecovery #NHSReset
Do you have dry eye disease? Aston University is now recruiting for a clinical research study for a new treatment that aims to significantly reduce symptoms of dry eye and provide long-term relief. Please share... #dryeye #dryeyedisease #ophthalmology https://www.nu-vision.co.uk/news/doors
